Labcorp Q3 revenue beats on organic growth, operating efficiencies
LH•LH•LH•LH•Labcorp’s third-quarter revenue rose 6.9% year over year to $3.81 billion, above the $3.76 billion analyst estimate, while adjusted EPS increased 14.5% to $4.78. The company raised its 2026 revenue growth outlook to 5.9%-6.7% and adjusted EPS guidance to $18.30-$18.70.
Labcorp reported third-quarter revenue of $3.81 billion, up 6.9% year over year and above the $3.76 billion analyst consensus. Adjusted EPS from continuing operations was $4.78, up 14.5% from a year earlier.
The company increased its 2026 revenue growth outlook to 5.9%-6.7% and adjusted EPS guidance to $18.30-$18.70. It expects Biopharma Laboratory Services revenue growth of 7.4%-8.4% and Diagnostics Laboratories revenue growth of 5.5%-6.2%.
Labcorp attributed higher adjusted operating income and margin to organic growth and operating efficiencies. It said recent acquisitions are expected to contribute to adjusted EPS and long-term growth, and cited new specialty tests and expanded access through acquisitions.
